Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Queen Mary University of London · Dutch Cancer Society · +36 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
494
total citations
- FWCI
- 67.02
- Percentile
- 100%
- References
- 25
Citations per year
Authors
227- TPThomas PowlesCorresponding
Queen Mary University of London
- MSMichiel S. van der Heijden
Dutch Cancer Society, The Netherlands Cancer Institute
- DCDaniel Castellano
Hospital Universitario 12 De Octubre
- MDMatthew D. Galsky
Mount Sinai Hospital, Tisch Hospital
- YLYohann Loriot
Inserm, Université Paris-Saclay, Institut Gustave Roussy
Topics & keywords
Topics
Keywords
- Durvalumab
- Medicine
- Tremelimumab
- Chemotherapy
- Metastatic Urothelial Carcinoma
- Oncology
- Open label
- Internal medicine
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- CCelgene
- EEndocyte
- EExelixis
- CTCelldex Therapeutics
- LLLes Laboratories Pierre Fabre
- COClovis Oncology
- IPINOVIO Pharmaceuticals
- IIncyte
- AEAstraZeneca España
- EEisai
- APAstellas Pharma
- IIpsen
- EPEUSA Pharma
- GGenentech
- ESEMD Serono
- PPharmacyclics
- FMFoundation Medicine